Cat. No.: HY-172590

LZ-07

Name: LZ-07
Brand: MedChemExpress
SKU: HY-172590
Price: 900.00 USD
Availability: InStock
Rating: 5 (1 reviews)

고객리뷰

Based on 1 Customer Validation

LZ-07 is a selective IRAK4 PROTAC degrader with DC₅₀ values of 1.14 nM (DOHH2) and 2.70 nM (TMD8). LZ-07 acts as a PI3Kδ kinase inhibitor with an IC₅₀ of 92 nM. By bridging IRAK4 and the CRBN E3 ubiquitin ligase, LZ-07 induces IRAK4 degradation via the ubiquitin-proteasome system, ablates both its kinase and scaffold functions, and thereby blocks downstream inflammatory signal transduction. LZ-07 can be used in research related to autoimmune diseases.
(Pink: IRAK4 ligand (HY-172591); Blue: Cereblon ligand (HY-W883357); Black: linker (HY-B0149)).

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity : 98.27%
화학식: C₄₂H₄₈N₁₄O₄
분자량:812.92

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

LZ-07 Chemical Structure

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
용액&용해도
- In Vitro
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

LZ-07 is a selective IRAK4 PROTAC degrader with DC₅₀ values of 1.14 nM (DOHH2) and 2.70 nM (TMD8). LZ-07 acts as a PI3Kδ kinase inhibitor with an IC₅₀ of 92 nM. By bridging IRAK4 and the CRBN E3 ubiquitin ligase, LZ-07 induces IRAK4 degradation via the ubiquitin-proteasome system, ablates both its kinase and scaffold functions, and thereby blocks downstream inflammatory signal transduction. LZ-07 can be used in research related to autoimmune diseases^[1]. (Pink: IRAK4 ligand (HY-172591); Blue: Cereblon ligand (HY-W883357); Black: linker (HY-B0149)).

IC₅₀ & Target

^[1]

IRAK4

1.14 nM (DC₅₀, DOHH2)

IRAK4

2.70 nM (DC₅₀, TMD8)

PI3Kδ

92 nM (IC₅₀)

TNF-α

IL-6

All PROTACs Isoforms :

All IRAK Isoforms :

All PI3K Isoforms :

All Interleukin Related Isoforms :

All TNF Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
TMD8	DC₅₀	2.70 nM	IRAK4 protein degradation in human TMD8 cells incubated for 16 hrs. IRAK4 protein degradation in human TMD8 cells incubated for 16 hrs.	j.cclet.2025.111033
DOHH-2	DC₅₀	1.14 nM	IRAK4 protein degradation in human DOHH2 cells incubated for 16 hrs. IRAK4 protein degradation in human DOHH2 cells incubated for 16 hrs.	j.cclet.2025.111033
PBMC	DC₅₀	4.471 nM	IRAK4 protein degradation in peripheral blood mononuclear cells from healthy donors incubated for 16 hrs. IRAK4 protein degradation in peripheral blood mononuclear cells from healthy donors incubated for 16 hrs.	j.cclet.2025.111033
PBMC	IC50	6.0 nM	Inhibition of LPS-induced IL-10 production in peripheral blood mononuclear cells from healthy donor P122071008C pretreated for 2 hrs followed by 24 hrs LPS stimulation, measured via ELISA. Inhibition of LPS-induced IL-10 production in peripheral blood mononuclear cells from healthy donor P122071008C pretreated for 2 hrs followed by 24 hrs LPS stimulation, measured via ELISA.	j.cclet.2025.111033
PBMC	IC50	6.6 nM	Inhibition of LPS-induced IL-6 production in peripheral blood mononuclear cells from healthy donor P122071008C pretreated for 2 hrs followed by 24 hrs LPS stimulation, measured via ELISA. Inhibition of LPS-induced IL-6 production in peripheral blood mononuclear cells from healthy donor P122071008C pretreated for 2 hrs followed by 24 hrs LPS stimulation, measured via ELISA.	j.cclet.2025.111033
PBMC	IC50	4.0 nM	Inhibition of LPS-induced TNF-α production in peripheral blood mononuclear cells from healthy donor P122071008C pretreated for 2 hrs followed by 24 hrs LPS stimulation, measured via ELISA. Inhibition of LPS-induced TNF-α production in peripheral blood mononuclear cells from healthy donor P122071008C pretreated for 2 hrs followed by 24 hrs LPS stimulation, measured via ELISA.	j.cclet.2025.111033
PBMC	IC50	2.0 nM	Inhibition of LPS-induced IL-1β production in peripheral blood mononuclear cells from healthy donor P122071008C pretreated for 2 hrs followed by 24 hrs LPS stimulation, measured via ELISA. Inhibition of LPS-induced IL-1β production in peripheral blood mononuclear cells from healthy donor P122071008C pretreated for 2 hrs followed by 24 hrs LPS stimulation, measured via ELISA.	j.cclet.2025.111033
PBMC	IC50	>10 μM	Cytotoxicity against peripheral blood mononuclear cells from healthy donor P122071008C. Cytotoxicity against peripheral blood mononuclear cells from healthy donor P122071008C.	j.cclet.2025.111033

In Vitro

LZ-07 (0.3-300 nM; 16 h) dose-dependently degrades IRAK4 in TMD8 and DOHH2 cells, with DC₅₀ values of 2.70 nM and 1.14 nM^[1].
LZ-07 (30-50 nM; 0.25 h-24 h) rapidly induces IRAK4 degradation in TMD8 and DOHH2 cells, with the maximum degradation achieved at 16 h^[1].
LZ-07 (1.52 nM-10 μM; pretreated for 2 h followed by stimulation with LPS (HY-D1056) for 24 h) potently inhibits the secretion of proinflammatory cytokines IL-10, IL-6, TNF-α and IL-1β in PBMCs derived from healthy donors, with IC₅₀ values ranging from 2.0 nM to 6.6 nM^[1].
LZ-07 (0.01-1000 nM; 16 h) induces degradation of IRAK4 in PBMCs, with a DC₅₀ of 4.47 nM^[1].

LZ-07 (30 nM; 8 h) prevents IRAK4 degradation in TMD8 and DOHH2 cells pretreated with MG132 (HY-13259), MLN4924 (HY-70062), Pomalidomide (HY-10984) or Compound E (HY-14176) due to inhibition of the proteasome or target binding, which demonstrates its dependence on the ubiquitin-proteasome system and dual-target binding^[1].
LZ-07 (up to 10 μM) shows no significant cytotoxicity in PBMCs^[1].
LZ-07 (0.1-3000 nM) inhibits PI3Kδ kinase activity in cell-free biochemical assays, with an IC₅₀ of 92 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

TMD8 and THP-1 cells
Concentration:

10 nM, 100 nM
Incubation Time:

16 h (TMD8), 24 h (THP-1)
Result:

Significantly degraded more than 65% of the IRAK4 protein at a concentration of 10 nM.

Western Blot Analysis^[1]

Cell Line:

TMD8 and DOHH2 cells
Concentration:

0.3, 1, 3, 10, 30, 100, 300 nM
Incubation Time:

16 h
Result:

Potently degraded IRAK4 in a dose-dependent manner, with a DC₅₀ of 1.14 nM in DOHH2 cells and 2.70 nM in TMD8 cells.

Western Blot Analysis^[1]

Cell Line:

TMD8 and DOHH2 cells
Concentration:

50 nM (TMD8), 30 nM (DOHH2)
Incubation Time:

0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 h
Result:

Began to degrade IRAK4 in a short period and reached the maximum degradation rate (D_max = 91%) at 16 hours.

Western Blot Analysis^[1]

Cell Line:

TMD8 and DOHH2 cells
Concentration:

30 nmol/L (after 2 hours of pre-treatment with 0.5 μmol/L MG132, 0.5 μmol/L MLN4924, 1 μmol/L Pomalidomide, or 1 μmol/L Compound E)
Incubation Time:

8 h
Result:

The IRAK4 degradation induced by LZ-07 was blocked by the proteasome inhibitor (MG132), ubiquitination inhibitor (MLN4924), and target competitors (Pomalidomide and Compound E), indicating that the degradation relies on the ubiquitin-proteasome system and dual target engagement.

Chemical Information

Appearance Solid
분자량 812.92
화학식 C₄₂H₄₈N₁₄O₄
Color Light yellow to green yellow
SMILES

CC1(CC1)NC2=NC(NC3=CN(C4CCN(C([C@@H]5CC[C@@H](CNC6=CN=C(C(NC7CCC(NC7=O)=O)=O)C=C6)CC5)=O)CC4)N=C3)=NC8=CC=C(C9=CN=CN=C9)N=C82
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

용액&용해도

In Vitro:

DMSO : 100 mg/mL (123.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2301 mL

6.1507 mL

12.3013 mL

5 mM

0.2460 mL

1.2301 mL

2.4603 mL

10 mM

0.1230 mL

0.6151 mL

1.2301 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Li, Zhen, et al. Developing potent anti-inflammatory IRAK4-targeting PROTACs with simplified CRBN ligands. Chinese Chemical Letters (2025): 111033.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2301 mL	6.1507 mL	12.3013 mL	30.7533 mL
	5 mM	0.2460 mL	1.2301 mL	2.4603 mL	6.1507 mL
	10 mM	0.1230 mL	0.6151 mL	1.2301 mL	3.0753 mL
	15 mM	0.0820 mL	0.4100 mL	0.8201 mL	2.0502 mL
	20 mM	0.0615 mL	0.3075 mL	0.6151 mL	1.5377 mL
	25 mM	0.0492 mL	0.2460 mL	0.4921 mL	1.2301 mL
	30 mM	0.0410 mL	0.2050 mL	0.4100 mL	1.0251 mL
	40 mM	0.0308 mL	0.1538 mL	0.3075 mL	0.7688 mL
	50 mM	0.0246 mL	0.1230 mL	0.2460 mL	0.6151 mL
	60 mM	0.0205 mL	0.1025 mL	0.2050 mL	0.5126 mL
	80 mM	0.0154 mL	0.0769 mL	0.1538 mL	0.3844 mL
	100 mM	0.0123 mL	0.0615 mL	0.1230 mL	0.3075 mL

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

LZ-07

All PROTACs Isoforms

All IRAK Isoforms

All PI3K Isoforms

All Interleukin Related Isoforms

All TNF Receptor Isoforms